EM
KITE

EnTrustPermal Management’s Kite Pharma, Inc. KITE Stock Holding History

EnTrustPermal Management’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$3.72M Buy
+20,700
New +$2.88M 1.55% 8

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

EnTrustPermal Management's KITE Position: Q3 2017 in Review

EnTrustPermal Management opened a new position in Kite Pharma, Inc. (KITE) in Q3 2017: 20,700 shares worth $3.72M. The stake represents 1.55% of the portfolio and ranks #8 among its holdings.

244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • EnTrustPermal Management held 20,700 shares of Kite Pharma, Inc. worth $3.72M as of Q3 2017.
  • Kite Pharma, Inc. was a new EnTrustPermal Management position in Q3 2017.
  • Kite Pharma, Inc. made up 1.55% of EnTrustPermal Management's portfolio in Q3 2017, its #8 holding.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on EnTrustPermal Management's 13F filing for Q3 2017, filed 14 Nov 2017.